Subcutaneous Levomepromazine Rescue (SLR) for High Grade Delayed Chemotherapy-induced Emesis (DCIE)

Anticancer Research

Volumn 23, Issue 6 D, 2003, Pages 5209-5212

  McCabe, H L ^a   Maraveyas, A ^a  

^a PRINCESS ROYAL HOSPITAL   (United Kingdom)

Author keywords

Anti emetics; Chemotherapy; Delayed emesis; Levomepromazine; Rescue

Indexed keywords

ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE DERIVATIVE; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IRINOTECAN; LEVOMEPROMAZINE; METHOTREXATE; METOCLOPRAMIDE; NAVELBINE; ONDANSETRON; OXALIPLATIN; PACLITAXEL;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; FEMALE; HUMAN; HYPOTENSION; LUNG CANCER; MALE; OVARY CANCER; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; METHOTRIMEPRAZINE; MIDDLE AGED; NAUSEA; NEOPLASMS; VOMITING;

EID: 0842321834     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Roila F, Tonato M, Cognetti F et al: Prevention of cisplatin-induced emesis: a double-blind multicentre randomised crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9: 675-8, 1991.
2. De Mulder PH, Seynaeve C, Vermorker JB, van Liessum PA, Mols-Jevdevic S, Allman EL, Beranek P and Verweij J: Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicentre, randomised, double blind, crossover study. Ann Intern Med 113(11): 834-840, 1990.
3. Fauser AA, Fellhauer M, Hoffman M, Link H, Schlimok G and Gralla RJ: Guidelines for antiemetic therapy: acute emesis. Eur J Cancer 35: 361-370, 1999.
4. Gralla RJ, Osoba D, Kris MG et al: Recommendations for the use of antiemetics: Evidence-based clinical practice guidelines. J Clin Onc 9: 2971-2994, 1999.
5. Twycross RG, Barkby GD and Hallwood PM: The use of low dose levomepromazine (methotrimeprazine) in the management of nausea and vomiting. Progress in Palliative Care 5(2): 49-53, 1997.
6. Skinner J and Skinner A: Levomepromazine for nausea and vomiting in advanced cancer. Hosp Med 60(8): 568-70, 1999.
7. Higi M, Niederle N, Bierbaum W Schimdt CG and Seeber S: Pronounced anti-emetic activity of the anti-psychotic drug levomepromazine in patients receiving cancer chemotherapy. J Cancer Res Clin Oncol 97: 81-86, 1980.
8. Martin M, Diaz-Rubio E, Sanchez Duran A and Almenarez J: A pilot study of levomepromazine in the treatment of refractory vomiting following chemotherapy. Oncologica 11(7): 348-351, 1988.
9. McCabe HL, Lind MJ and Maraveyas A: The efficacy of levomepromazine (nozinan) in delayed chemotherapy induced emesis (DCIE). Proc Am Soc Clin Onc Abstract number #2941, 2001.
10. Dubersarsky CG, Lavarda M, Rizzi M, Ruibal S, Ortiz V, Giraudo A and Jarchum GD: Levomepromazine as salvage antiemetic therapy for acute or delayed chemotherapy associated emesis. Proc Am Soc Clin Onc Abstract number #3103, 2003.